Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Drug Profile

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Alternative Names: Antigen-based therapy (ABT) - Diamyd Medical; Diabetes-mellitus-vaccine-Diamyd-Medical; Diabetes-mellitus-vaccine-Diamyd-Therapeutics; Diamyd; GAD-65 - Diamyd Medical; GAD-Alum vaccine; GAD-Alum vaccine - Diamyd Medical; GAD-antigen therapy (Diamyd); rhGAD65 - Diamyd Medical

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical AB; Linkoping University; Lund University; University of Alabama at Birmingham
  • Class Antihyperglycaemics; Diabetes mellitus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Latent autoimmune diabetes in adults; Type 1 diabetes mellitus

Most Recent Events

  • 24 Oct 2016 Interim efficacy, adverse event data and immunological data from the DIAGNODE-1 trial in Type-I diabetes mellitus released by Diamyd Medical
  • 07 Sep 2016 Diamyd Medical completes enrolment in the phase II EDCR IIa trial for Type-1 diabetes mellitus in Sweden (NCT02464033)
  • 23 Mar 2016 Preliminary interim adverse events data from a phase IIa EDCR trial in Type-I diabetes mellitus released by Diamyd Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top